Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated withchemo-radiotherapy

doi:10.3748/wjg.v12.i37.6032

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 37

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2005)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

222

HTML

1502

Figures (1-1)

148

Tables (1-6)

133

Sum=2005

Oct 7, 2006 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Oct 7, 2006; 12(37): 6032-6036
Published online Oct 7, 2006. doi: 10.3748/wjg.v12.i37.6032

Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated withchemo-radiotherapy

RN Zárate R, F Arias, E Bandres, E Cubedo, R Malumbres, J García-Foncillas

RN Zárate R, E Bandres, E Cubedo, R Malumbres, J García-Foncillas, Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, 36 Pio XII Ave, Pamplona 31008, Spain

F Arias, Navarra Hospital center, s/n Irunlarrea Street, Pamplona 31008, Spain

Supported by a grant from the Navarra Government 70/2004

Correspondence to: Ruth Zárate, PhD, Laboratory of Biotechnology, University Clinic of Navarra, 36 Pio XII Ave, Pamplona 31008, Spain. rzarate@unav.es

Telephone: +34-948-255400-1127 Fax: +34-948-296795

Received: June 7, 2006
Revised: June 22, 2006
Accepted: July 7, 2006
Published online: October 7, 2006

Abstract

AIM: To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer.

METHODS: We used PCR-RFLP to evaluate the genetic XPD Lys751Gln polymorphisms in 44 patients with stage III (48%) and IV (20%) gastric cancer treated with surgery following radiation therapy plus 5-fluorouracil/leucovorin based chemotherapy.

RESULTS: Statistical analysis showed that 75% (12 of 16) of relapse patients showed Lys/Lys genotype more frequently (P = 0.042). The Lys polymorphism was an independent predictor of high-risk relapse-free survival from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P = 0.036) and Kaplan-Meir test (P = 0.027, log-rank test).

CONCLUSION: XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to chemo-radiotherapy in resected gastric cancer patients.

Keywords: Xeroderma pigmentosum group D gene, Polymorphism, Gastric cancer, Radiotherapy